Literature DB >> 9740686

Multiple drug resistance parameter expression in ovarian cancer.

F Joncourt1, K Buser, H Altermatt, M Bacchi, A Oberli, T Cerny.   

Abstract

OBJECTIVE: Drug resistance represents a complex problem for the treatment of ovarian cancer. This study was undertaken to assess several putative resistance parameters (DRP) in parallel in cancer tissue from newly diagnosed patients with ovarian cancer in order to establish possible correlations to known clinical factors and prognosis.
MATERIAL AND METHODS: Tumor and adjacent tumor free ovarian tissue samples from 39 consecutive, untreated female patients with ovarian cancer were obtained and as potential DRPs, the level of glutathione (GSH), the activities of glutathione S-transferase (GST), glutathione-peroxidase (GPx), O6-alkylguanine-DNA alkyltransferase (Atase), and topoisomerase II (TOPO) were assessed biochemically, and P-glycoprotein (Pgp) was assessed by Western blotting.
RESULTS: Interindividual variations were high and each patient exhibited an individual profile of resistance factor expression. Levels of GSH were increased with stage (linear trend: P < 0.002), and GST, GPx, and Atase showed a similar tendency. With few exceptions no correlation was found between the DRPs and other prognostic characteristics. All tested DRPs except Pgp showed significantly higher levels/activities in tumor tissues than in the surrounding tumor free tissues (P < 0.05). The tested DRPs were found not to influence response to treatment.
CONCLUSIONS: It is concluded that elevated DRPs reflect an intrinsic pattern of components of the detoxifying system in the tumor tissue. This pattern differs between patients and may partly explain the difficulty to assess the clinical importance of individual DRPs in order to translate them into recommendations for specific therapies. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9740686     DOI: 10.1006/gyno.1998.5085

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

Review 1.  Overcoming drug resistance in ovarian carcinoma.

Authors:  P M Fracasso
Journal:  Curr Oncol Rep       Date:  2001-01       Impact factor: 5.075

2.  In vivo MR studies of glycine and glutathione metabolism in a rat mammary tumor.

Authors:  Peter E Thelwall; Nicholas E Simpson; Zahid N Rabbani; M Daniel Clark; Roxana Pourdeyhimi; Jeffrey M Macdonald; Stephen J Blackband; Michael P Gamcsik
Journal:  NMR Biomed       Date:  2011-07-12       Impact factor: 4.044

Review 3.  Circadian rhythm connections to oxidative stress: implications for human health.

Authors:  Melissa Wilking; Mary Ndiaye; Hasan Mukhtar; Nihal Ahmad
Journal:  Antioxid Redox Signal       Date:  2013-04-24       Impact factor: 8.401

Review 4.  Glutathione levels in human tumors.

Authors:  Michael P Gamcsik; Mohit S Kasibhatla; Stephanie D Teeter; O Michael Colvin
Journal:  Biomarkers       Date:  2012-08-20       Impact factor: 2.658

5.  Detection and analysis of multiple biomarkers in ovarian cancer: clinical significance in diagnosis, treatment, and prognosis evaluation.

Authors:  Rui Ji; Yong Li; Chenyun He; Xinghua Zhu; Aiqin He; Yunyan Lu
Journal:  Gland Surg       Date:  2020-12

Review 6.  Overcome Cancer Cell Drug Resistance Using Natural Products.

Authors:  Pu Wang; Hua Li Yang; Ying Juan Yang; Lan Wang; Shao Chin Lee
Journal:  Evid Based Complement Alternat Med       Date:  2015-09-01       Impact factor: 2.629

7.  Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis.

Authors:  Si Sun; Jing Cai; Qiang Yang; Yapei Zhu; Simei Zhao; Zehua Wang
Journal:  PLoS One       Date:  2016-11-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.